Global Information Lookup Global Information

Anacetrapib information


Anacetrapib
Names
Preferred IUPAC name
(4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4′-fluoro-2′-methoxy-5′-(propan-2-yl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one
Other names
MK-0859
Identifiers
CAS Number
  • 875446-37-0 checkY
3D model (JSmol)
  • Interactive image
ChEMBL
  • ChEMBL1800807 ☒N
ChemSpider
  • 9731205 checkY
KEGG
  • D08855 checkY
PubChem CID
  • 11556427
UNII
  • P7T269PR6S checkY
CompTox Dashboard (EPA)
  • DTXSID90236452 Edit this at Wikidata
InChI
  • InChI=1S/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1 checkY
    Key: MZZLGJHLQGUVPN-HAWMADMCSA-N checkY
  • InChI=1/C30H25F10NO3/c1-14(2)22-11-23(25(43-4)12-24(22)31)21-6-5-18(28(32,33)34)9-17(21)13-41-15(3)26(44-27(41)42)16-7-19(29(35,36)37)10-20(8-16)30(38,39)40/h5-12,14-15,26H,13H2,1-4H3/t15-,26-/m0/s1
    Key: MZZLGJHLQGUVPN-HAWMADMCBN
SMILES
  • O=C2O[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)[C@@H](N2Cc4c(c3cc(c(F)cc3OC)C(C)C)ccc(c4)C(F)(F)F)C
Properties
Chemical formula
 C30H25F10NO3
Molar mass 637.51 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease.[1] In 2017 its development was abandoned by Merck.[2]

  1. ^ Gutstein DE, Krishna R, Johns D, et al. (2012). "Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction". Clinical Pharmacology & Therapeutics. 91 (1): 109–122. doi:10.1038/clpt.2011.271. PMID 22130116. S2CID 36510986.
  2. ^ "Merck says will not seek approval of cholesterol treatment". Reuters. 2017. Retrieved 18 October 2017.

and 9 Related for: Anacetrapib information

Request time (Page generated in 0.5196 seconds.)

Anacetrapib

Last Update:

Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017...

Word Count : 226

CETP inhibitor

Last Update:

Succeeded: Anacetrapib. In 2017, the REVEAL trial based on more than 30,000 participants showed a modest benefit of the addition of anacetrapib to statin...

Word Count : 781

Aortic aneurysm

Last Update:

as a screening tool for those most at risk: men over the age of 65. Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density...

Word Count : 3360

Dyslipidemia

Last Update:

ester transfer protein (CETP) inhibitors include the agents torcetrapib, anacetrapib and obicetrapib. They block transfer of cholesterol from "good" HDL particles...

Word Count : 2961

Cholesteryl ester transfer protein

Last Update:

inhibitors were previously under development. One was Merck's MK-0859 anacetrapib, which in initial studies did not increase blood pressure. In 2017, its...

Word Count : 1736

Evacetrapib

Last Update:

treatment of dyslipidemia, though significant caution is warranted. Anacetrapib is the fourth CETP inhibitor being tried for cardiovascular benefit In...

Word Count : 708

Nir Barzilai

Last Update:

Merck conducted early-stage clinical trials but ultimately abandoned Anacetrapib. The diabetes research is led by CohBar Inc., a biotech company that...

Word Count : 999

Dalcetrapib

Last Update:

1093/eurheartj/ehs019. PMC 3345558. PMID 22345126. Gail Parziale. "Dalcetrapib and Anacetrapib: a Tale of Two CETPs". Archived from the original on 2011-12-19. Schwartz...

Word Count : 907

Torcetrapib

Last Update:

chloroformate completes the synthesis of torcetrapib (8). CETP inhibitor Anacetrapib, CETP inhibitor undergoing development by Merck Dalcetrapib, CETP inhibitor...

Word Count : 1638
PDF Search Engine © AllGlobal.net